Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.35 |
| ▸ | CNR1 | P21554 | 11/20 | 0.35 |
| ▸ | GRN | P28799 | 4/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283406 | 0.83 | GRN (0.38) | CNR2CNR1GRNSORT1KDM4E | |
| Hydrochloric Acid SCHEMBL4281396 | 0.78 | CA1 (0.35) | CNR2CNR1GRNSORT1KDM4E | |
| SCHEMBL13705111 | 0.77 | PARP1 (0.53) | GRNSORT1MEN1KMT2ANPC1 | |
| SCHEMBL4281250 | 0.77 | KDM4E (0.46) | KDM4EKMT2A | |
| SCHEMBL4291155 | 0.71 | SMN1; SMN2 (0.38) | KDM4E | |
| SCHEMBL4288567 | 0.71 | FAAH (0.34) | KMT2A | |
| SCHEMBL4281879 | 0.70 | KDM4E (0.36) | KDM4EMEN1KMT2A | |
| SCHEMBL4286066 | 0.69 | RAB9A (0.35) | KDM4E | |
| SCHEMBL4281381 | 0.69 | HTR1A (0.44) | CNR2KMT2A | |
| SCHEMBL4291731 | 0.68 | SMN1; SMN2 (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CNR2 3580/4885CNR1 3488/4885GRN 3093/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | CNR2 3580/4885CNR1 3488/4885GRN 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.